1. Guest, the 'News in Brief' for the week beginning 30th January 2023 is here.
    Dismiss Notice
  2. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Quick Navigation Menu

General Links

Forum List

  1. Welcome to Science For ME
  2. Welcome: About the Forum, Our Values
  3. ME/CFS and Long Covid news
  4. ME/CFS and Long Covid news
  5. General ME/CFS news
  6. ME/CFS research news
  7. Long Covid news
  8. Psychosomatic news - ME/CFS and Long Covid
  9. Regional news
  10. News from organisations
  11. Weekly ME news in brief
  12. ME/CFS and Long Covid research
  13. ME/CFS and Long Covid research
  14. ME/CFS research
  15. Long Covid research
  16. Psychosomatic research - ME/CFS and Long Covid
  17. Recruitment into current ME/CFS research studies
  18. Other news and research
  19. Other news and research
  20. 'Conditions related to ME/CFS' news and research
  21. Other psychosomatic news and research
  22. Research methodology news and research
  23. Other health news and research
  24. Epidemics (including Covid-19, not Long Covid)
  25. Resources
  26. Resources
  27. Resources
  28. Science library (Read only)
  29. Training courses
  30. Advocacy and Fundraising
  31. Advocacy
  32. Advocacy Action Alerts
  33. General Advocacy Discussions
  34. General disability topics and advocacy
  35. Advocacy Projects and Campaigns
  36. Petitions
  37. Fundraising
  38. Open Letters and Replies
  39. MEpedia
  40. Guidelines, reviews and disease coding
  41. ME/CFS related guidelines, reviews, disease coding
  42. Disease coding
  43. 2021 Cochrane Exercise Therapy Review
  44. 2021 USA CDC ME/CFS Diagnosis and Treatment Review
  45. 2020 UK NICE ME/CFS Guideline
  46. 2020 UK NICE Long Covid Guideline
  47. Other guidelines
  48. Other reviews with a public consultation process
  49. Discussion topics
  50. Research quality and methodology discussions
  51. Laboratory and genetic testing, medical imaging
  52. Physical testing (e.g. CPET, actimetry)
  53. Subjective outcome measures (questionnaires)
  54. Trial design including bias, placebo effect
  55. Other research methodology topics
  56. Causes, Epidemiology, Criteria, Naming discussions
  57. Possible causes and predisposing factor discussion
  58. Diagnostic Criteria and Naming Discussions
  59. Epidemiology (incidence, prevalence, prognosis)
  60. Symptoms and signs discussions
  61. General and other signs and symptoms
  62. Post-Exertional malaise and fatigue
  63. Pain and Inflammation
  64. Sleep Disturbance
  65. Cardiovascular and exercise physiology (CPET)
  66. Orthostatic intolerance
  67. Neurological/cognitive/vision
  68. Blood (e.g. coagulation, cell stiffness)
  69. Immunological
  70. Hypersensitivity and Intolerance Reactions
  71. Gastrointestinal and Urinary
  72. Cellular (mitochondria, metabolites, cytokines)
  73. Treatment discussions
  74. Drug and supplement treatments
  75. Orthostatic intolerance treatments
  76. Nutrition, food sensitivity, microbiome treatments
  77. Other treatments
  78. Psychosomatic theories and treatments discussions
  79. Other specific illnesses discussions
  80. Fibromyalgia and Connective Tissue Disorders
  81. Infections: Lyme, Candida, EBV ...
  82. Endocrine: Thyroid, Adrenal, Diabetes
  83. Immune: Autoimmune and Mast Cell Disorders
  84. Neurological diseases
  85. Vitamin B12, D and other deficiencies
  86. Gulf War Illness
  87. Other specific illnesses
  88. Doctors, clinics and organisations discussions
  89. General clinical care
  90. USA clinics and doctors
  91. UK clinics and doctors
  92. Other clinics and doctors
  93. Organisations relevant to ME/CFS and Long Covid
  94. Living with ME/CFS discussions
  95. Home adaptations, mobility and personal care
  96. Relationships and coping
  97. Monitoring and pacing
  98. Work, Finances and Disability Insurance
  99. Caregiver support
  100. General ME/CFS discussions
  101. General ME/CFS discussion
Close